These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. COX-2 status in relation to tumor microvessel density and VEGF expression: analysis in ovarian carcinoma patients with low versus high survival rates. Raspollini MR, Amunni G, Villanucci A, Boddi V, Baroni G, Taddei A, Taddei GL. Oncol Rep; 2004 Feb; 11(2):309-13. PubMed ID: 14719060 [Abstract] [Full Text] [Related]
6. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. Ueda M, Hung YC, Terai Y, Kanda K, Kanemura M, Futakuchi H, Yamaguchi H, Akise D, Yasuda M, Ueki M. Clin Cancer Res; 2005 May 01; 11(9):3225-32. PubMed ID: 15867217 [Abstract] [Full Text] [Related]
7. [Relationship between cyclooxygenase-2 protein expression, prostaglandins levels and biologic behavior in ovarian carcinoma tissue]. Tang L, Wang M, Ma J. Zhonghua Fu Chan Ke Za Zhi; 2002 Nov 01; 37(11):687-90. PubMed ID: 12487927 [Abstract] [Full Text] [Related]
9. Ovarian serous carcinoma: relationship of p53 and bcl-2 with tumor angiogenesis and VEGF expression. Crasta JA, Mishra S, Vallikad E. Int J Gynecol Pathol; 2011 Nov 01; 30(6):521-6. PubMed ID: 21979585 [Abstract] [Full Text] [Related]
10. [Expression and significance of cyclooxygenase-2 in human pancreatic carcinomas]. Wang HX, Chen QK. Ai Zheng; 2003 Jun 01; 22(6):649-52. PubMed ID: 12948419 [Abstract] [Full Text] [Related]
12. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. Fauvet R, Dufournet C, Poncelet C, Uzan C, Hugol D, Daraï E. J Surg Oncol; 2005 Dec 15; 92(4):337-43. PubMed ID: 16299808 [Abstract] [Full Text] [Related]
13. Cyclooxygenase-2 expression in borderline ovarian tumors. Ferrandina G, Zannoni GF, Ranelletti FO, Legge F, Gessi M, Salutari V, Gallotta V, Lauriola L, Scambia G. Gynecol Oncol; 2004 Oct 15; 95(1):46-51. PubMed ID: 15385109 [Abstract] [Full Text] [Related]
14. Immunohistochemical expression of the cyclooxygenase-2 (COX-2) in gastric cancer. The correlations with the tumor angiogenesis and patients' survival. Lazăr D, Tăban S, Ardeleanu C, Simionescu C, Sporea I, Cornianu M, Vernic C. Rom J Morphol Embryol; 2008 Oct 15; 49(3):371-9. PubMed ID: 18758643 [Abstract] [Full Text] [Related]
15. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Ali-Fehmi R, Morris RT, Bandyopadhyay S, Che M, Schimp V, Malone JM, Munkarah AR. Am J Obstet Gynecol; 2005 Mar 15; 192(3):819-25. PubMed ID: 15746677 [Abstract] [Full Text] [Related]
16. Prognostic significance of COX-2 expression and correlation with Bcl-2 and VEGF expression, microvessel density, and clinical variables in classical Hodgkin lymphoma. Koh YW, Park C, Yoon DH, Suh C, Huh J. Am J Surg Pathol; 2013 Aug 15; 37(8):1242-51. PubMed ID: 23851330 [Abstract] [Full Text] [Related]
19. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma. Bolat F, Gumurdulu D, Erkanli S, Kayaselcuk F, Zeren H, Ali Vardar M, Kuscu E. Pathol Res Pract; 2008 Aug 15; 204(6):379-87. PubMed ID: 18343598 [Abstract] [Full Text] [Related]